Tag: Gastroesophageal Cancer
-

Jazz Wins First-Line FDA Approval for Ziihera in HER2-Positive Gastroesophageal Cancer
The FDA approved Ziihera for first-line HER2-positive gastroesophageal adenocarcinoma, strengthening Jazz Pharmaceuticals’ solid-tumor oncology strategy.